Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France

Digestive Diseases and Sciences

Volumn 61, Issue 10, 2016, Pages 3072-3083

  Marcellin, Patrick ^a   Zoulim, Fabien ^b   Hézode, Christophe ^c   Causse, Xavier ^d   Roche, Bruno ^e   Truchi, Régine ^f   Pauwels, Arnaud ^g   Ouzan, Denis ^h   Dumortier, Jérôme ⁱ   Pageaux, Georges Philippe ^j   Bourlière, Marc ^k   Riachi, Ghassan ^l   Zarski, Jean Pierre ^m   Cadranel, Jean François ⁿ   Tilliet, Valérie ^o   Stern, Christiane ^o   Pétour, Pascal ^o   Libert, Olivier ^o   Consoli, Silla M ^p   Larrey, Dominique ^j  

^a BEAUJON HOSPITAL   (France)

^b CROIX ROUSSE HOSPITAL   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d Centre Hospitalier Régional   (France)

^e HÔPITAL PAUL BROUSSE   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g CENTRE HOSPITALIER DE GONESSE   (France)

^h INSTITUT ARNAULT TZANCK   (France)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

^j HÔPITAL SAINT ELOI   (France)

^k HÔPITAL SAINT JOSEPH   (France)

^l HÔPITAL CHARLES NICOLLE   (France)

^m CHU La Tronche and University   (France)

ⁿ CENTRE HOSPITALIER LAENNEC   (France)

^o Gilead Sciences   (France)

^p HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

HBV; Real world; Routine practice; Tenofovir

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; CREATININE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; PHOSPHORUS; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; TENOFOVIR;

ABDOMINAL PAIN; AGED; ANTIVIRAL THERAPY; ARTICLE; ASCITES; ASTHENIA; BACTERIAL PERITONITIS; CHRONIC HEPATITIS B; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; ESOPHAGUS VARICES; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FRANCE; GAIT DISORDER; HEADACHE; HEPATIC ENCEPHALOPATHY; HUMAN; HYPOPHOSPHATEMIA; KIDNEY FAILURE; KIDNEY FUNCTION TEST; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MONOTHERAPY; MULTICENTER STUDY; MUSCLE SPASM; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; NAUSEA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; RELAPSE; SEROCONVERSION; SIDE EFFECT; THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL IMPAIRMENT; WEIGHT REDUCTION; ADULT; BLOOD; CHEMICALLY INDUCED; HEPATITIS B, CHRONIC; KIDNEY DISEASE; MIDDLE AGED; TREATMENT OUTCOME; VIRUS LOAD; VOMITING;

ABDOMINAL PAIN; ADULT; AGED; ANTIVIRAL AGENTS; ASTHENIA; DIARRHEA; DNA, VIRAL; FEMALE; FRANCE; HEADACHE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; HYPOPHOSPHATEMIA; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; SEROCONVERSION; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD; VOMITING;

EID: 84955564571     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-4027-8     Document Type: Article

References (24)

1. World Health Organization. Hepatitis B Fact Sheet No 204. Updated July 2014. http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed June 2015.
2. Chu JJ, Wörmann T, Popp J, et al. Changing epidemiology of hepatitis B and migration—a comparison of six Northern and North-Western European countries. Eur J Public Health. 2013;23:642–647.
3. Zarski JP. Epidémiologie de l’hépatite chronique B. Presse Med. 2006;35:304–307.
4. Marcellin P, Pequignot F, Delarocque-Astagneau E, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol. 2008;48:200–207.
5. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101:1797–1803.
6. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.
7. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686.
8. Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921–931.
9. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2012;57:167–185.
10. Dhumeaux D. Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C. Rapport de Recommandations 2014. http://www.sante.gouv.fr/IMG/pdf/Rapport_Prise_en_charge_Hepatites_2014.pdf. Accessed June 2015.
11. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.
12. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.
13. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132–143.
14. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.
15. Marcellin P, Gane EJ, Flisiak R, et al. Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials. Hepatology. 2014;60:313A.
16. Lampertico P, Soffrendi R, Yurdaydin C, et al. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favourable renal safety profile but does not prevent HCC in patients with or without cirrhosis. Hepatology. 2013;58:653A.
17. van Bömmel F, Zoutendijk R, de Man R, et al. A European field study of the efficacy and safety of tenofovir disoproxil fumarate (TDF) monotherapy in patients with prior failure to other nucleoside/nucleotide analogues. J Hepatol. 2012;57:S544.
18. Girerd X, Hanon O, Anagnostopoulos K, Ciupek C, Mourad JJ, Consoli S. Assessment of antihypertensives compliance using a self-administered questionnaire: development and use in hypertension clinics. Presse Med. 2001;30:1044–1048.
19. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 2010;139:1207–1217.
20. van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51:73–80.
21. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531.
22. Lock E. Sensitive and early markers of renal injury: where are we and what is the way forward? Toxicol Sci. 2010;116:1–4.
23. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis. 2013;57:1773–1781.
24. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49(Suppl):S185–S195.